ZUG, Switzerland--(EON: Enhanced Online News)--PSI CRO has received top honors in the bi-annual CenterWatch Global Investigator Site Survey 2017 for the second time in a row. The survey results published April 3, 2017 by CenterWatch measured 37 project attributes in more than 1,300 investigative sites across 15 countries.
“The most important being clarity of mutual expectations, a helpful, enthusiastic attitude, and the relentless building of trust. Only then can we count on dedication from the sites in reaching on-time enrollment goals in our highly competitive environment.”
“We’re pleased with these results. PSI is dedicated to being the best CRO to work with and for,” says PSI’s President Nick Sinackevich. “It is a great honor to receive such a high award from our investigators worldwide for the second time running. It validates that we’re on the right track.”
After receiving top honors in 2015, PSI created a company-wide intention to not only hold on to the ranking, but improve in critical areas. “PSI’s key differentiator is on-time patient enrollment. Needless to say, successful collaboration with our sites is key to our success. All PSI’s country managers and clinical operations managers throughout the company know that paying attention to site relationships in their respective territories is a priority,” said Andrea Cracraft, Clinical Operations Director for the US. “It is remarkable that as a result, compared to the last CenterWatch Survey in 2015, PSI not only remained the Number One Global CRO, but our ratings have grown by an additional 21% across all attributes.”
From the official CenterWatch press release:
The CenterWatch Global Investigative Site Relationship Survey was first launched in 1997. This year’s survey was conducted online from October 2016 to January 2017, and asked principal investigators, sub-investigators and study coordinators to rate the sponsors with whom they worked during the past two years on 37 relationship attributes, from study planning to innovation, and to rate the importance of those attributes as well. Key changes to the survey included new attributes that addressed issues related to patient-centric protocol design and risk-based monitoring. A total of 12 CROs with sufficient sample sizes were profiled in the analysis.
The survey results showed a more strategic view of site relationships among CROs, something that PSI has developed for years. “There are many elements in building a strategic CRO-site partnerships,” said Olga Alfonsova, PSI’s Global Head of Development. “The most important being clarity of mutual expectations, a helpful, enthusiastic attitude, and the relentless building of trust. Only then can we count on dedication from the sites in reaching on-time enrollment goals in our highly competitive environment.”
PSI’s mission is to be the best CRO in the world as measured by their clients, employees and investigators. The company reports exceptionally high repeat business rates, low staff turnover, and top rankings from sites all over the world. After 20 years in the industry, PSI continues to grow organically, maintaining a reputation of delivery and service, while remaining private and independent.
About PSI CRO:
PSI is a privately-owned, full-service contract research organization (CRO), operating globally. PSI’s reputation on the market place is that of a no-nonsense CRO, capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSI’s global reach supports the operations of clinical trials across multiple countries and continents. PSI is known to be highly selective about the work that they pursue. PSI has exceptionally high repeat and referral business rates, while maintaining minimal staff turnover indicative of its commitment to be the best CRO in the world as measured by its customers and its employees. In bi-annual CenterWatch Investigator Surveys of 2015 and 2017 PSI was repeatedly voted Number One Global CRO.
Global headquarters are located in Zug (Zürich), Switzerland at 113a Baarerstrasse 6300.